January/February #185 : Treatment: New Fusion Inhibitor, Integrase Inhibitor - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

Heart to Heart

Myths of Black MSM

From the Editor

Sowing the Seeds of Love

Feedback

Letters-January/February 2013

The POZ Q+A

Standing Against Stigma

POZ Planet

Storm Troopers

Say What-Fran Lebowitz

Oh No Canada

Signs of the Times

For Your Consideration...

Climb Every Mountain

Grindr IQ

Care and Treatment

Using Condoms As Directed

English Lessons

Comprehensive Care Is Possible

HIV, Meds and Booze

Research Notes

Cure: HDAC Inhibitors May Need Combos

Prevention: Revisiting HIV in Semen

Treatment: New Fusion Inhibitor, Integrase Inhibitor

POZ Survey Says

Full Disclosure

POZ Heroes

Minister of HIV

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

January / February 2013

Treatment: New Fusion Inhibitor, Integrase Inhibitor

by Benjamin Ryan

The 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco brought promising news of new, long-acting antiretrovirals to benefit people with drug-resistant strains of HIV. Chinese researchers announced results from early clinical trials of an experimental fusion inhibitor called Albuvirtide (FB006M), which boasts a half-life that’s long enough to possibly allow for only once-weekly dosing. This addition to the anti-HIV arsenal would finally provide relief from twice-daily injections required for Fuzeon, which has been the only fusion inhibitor on the market for the past decade but has been vital for multi-drug resistant patients. Meanwhile, ViiV Healthcare presented data at the conference from its experimental integrase inhibitor S/GSK1265744, which has proved potent against HIV strains resistant to Isentress (raltegravir) and elvitegravir. Currently conducting Phase IIb studies, ViiV is investigating the potential for once-a-month injectable dosing.

Search: 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy, drug-resistant HIV, fusion inhibitor, Albuvirtide, FB006M, Fuzeon, ViiV Healtchare, S/GSK1265744, integrase inhibitor

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    Poz_Qt
    Columbus
    Ohio


    usuallyhappy
    Palm Springs
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.